SCHEMBL727874

SCHEMBL727874

CC(C)c1cccc(C=O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 3/20 0.56
ALDH1A1 P00352 4/20 0.48
HDAC4 P56524 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MDM4 O15151 1/20 0.47
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47
CA5A P35218 1/20 0.47
HTT P42858 1/20 0.47
MDM2 Q00987 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HDAC2 Q92769 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30291836 1.00 TYR (0.56) TYRALDH1A1HDAC4HDAC8CA1
SCHEMBL8406756 0.88 TYR (0.44) TYRALDH1A1HDAC4HDAC8CA1
SCHEMBL29756201 0.83 ALDH1A1 (0.50) TYRALDH1A1CA1CA2CA9
SCHEMBL31124696 0.83 ALDH1A1 (0.48) TYRALDH1A1CA1CA2CA9
SCHEMBL2263076 0.83 ALDH1A1 (0.48) TYRALDH1A1CA1CA2CA9
SCHEMBL11467711 0.82 TYR (0.45) TYRALDH1A1HDAC4HDAC8CA1
Benzene SCHEMBL28222842 0.82 UNG (0.44) TYRALDH1A1CA1CA2CA9
SCHEMBL2935867 0.80 CCNB2 (0.55) TYRALDH1A1HDAC4HDAC8CA1
SCHEMBL2935869 0.80 CCNB2 (0.55) TYRALDH1A1HDAC4HDAC8CA1
SCHEMBL4099672 0.80 HDAC4 (0.53) TYRALDH1A1HDAC4HDAC8CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025090929-A1 APPARATUS, SYSTEMS, AND METHODS FOR DETECTING HYPOGLYCEMIA THE TRUSTEES OF INDIANA UNIVERSITY (US) 2025-05-01 WO claimed
JP-4754142-B2 2011-08-24 JP claimed
US-6723883-B1 REACTING A BENZALDEHYDE COMPOUND WITH AN ALKANALDEHYDE; CASCADE SYSTEM BASF AKTIENGESELLSCHAFT (DE) 2004-04-20 US claimed
EP-1220824-B1 CONTINUOUS METHOD FOR PRODUCTION OF CINNAMALDEHYDE AND DIHYDROCINNAMALDEHYDE DERIVATIVES BASF AG (DE) 2004-02-11 EP claimed
EP-1220824-A1 CONTINUOUS METHOD FOR PRODUCTION OF CINNAMALDEHYDE AND DIHYDROCINNAMALDEHYDE DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2002-07-10 EP claimed
US-6380197-B1 FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES AVENTIS PHARMA S. A. (FR) 2002-04-30 US claimed
WO-2001027061-A1 CONTINUOUS METHOD FOR PRODUCTION OF CINNAMALDEHYDE AND DIHYDROCINNAMALDEHYDE DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2001-04-19 WO claimed
EP-1001943-A1 POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM Aventis Pharma S.A. (FR) 2000-05-24 EP claimed
WO-1999003843-A1 POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM RHONE-POULENC RORER S.A. (FR) 1999-01-28 WO claimed
EP-4103557-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-02-18 EP disclosed
EP-4692289-A1 PERFUME COMPOSITION AND ALICYCLIC ALCOHOL COMPOSITION MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2026-02-11 EP disclosed
US-12502378-B2 Monoacylglycerol lipase modulators for use in autism spectrum disorders JANSSEN PHARMACEUTICA NV (BE) 2025-12-23 US disclosed
EP-4180415-B1 ALIPHATIC DIAMINE ISOMERIZATION METHOD, DIISOCYANATE PRODUCTION METHOD, POLYURETHANE PRODUCTION METHOD, AND POLYURETHANE MITSUBISHI GAS CHEMICAL CO (JP) 2025-11-26 EP disclosed
US-20250312504-A1 VOLATILE COMPOSITION DISPENSER FOR COMPOSITIONS COMPRISING A META-(C1-C4 ALKOXY) SALICYLALDEHYDE THE PROCTER & GAMBLE COMPANY 2025-10-09 US disclosed
US-4415572-A CARDIOTONIC AND INOTROPIC AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1983-11-15 US disclosed
US-4374149-A HYPOTENSIVE AGENT AND VASODILATOR STERLING DRUG INC. (US) 1983-02-15 US disclosed
EP-0064690-A1 Process for the preparation of substituted benzaldehydes BAYER AG (DE) 1982-11-17 EP disclosed
US-4329495-A USEFUL AS ANALGESICS OR ANTICONVULSANTS, CHIRAL 2-(2-BENZYL-3-MERCAPTOPROPIONYLAMINO)-THIOBUTYRIC ACIDS, OR ALKANOL DERIVATIVES PFIZER INC. (US) 1982-05-11 US disclosed
US-4304790-A 2-(Alkylthio, alkylsulfinyl or alkylsulfonyl)-4-[2-anilinoalkylamino)-1-hydroxyethyl]phenols and derivatives thereof SCHERING CORPORATION (US) 1981-12-08 US disclosed
US-4208536-A PROMOTERS COMPRISING AROMATIC ALDEHYDES OR ACETALS OR A BENZOHYDROL RHONE-POULENC INDUSTRIES (FR) 1980-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12502378-B2 Monoacylglycerol lipase modulators for use in autism spectrum disorders LIPC, LPL, MGLL TYR 3661/4885ALDH1A1 266/4885HDAC4 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.